

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ernest J. Lee, et al. :

APPLICATION NO.: 10/626,275 : Examiner: Schlientz, Nathan W.

FILING DATE: July 24, 2003 : Group Art Unit: 1616

TITLE: PRAMIPEXOLE ONCE-DAILY :  
DOSAGE FORM

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). Both of these documents are from recent prosecution of copending application 10/626,166, over which the Examiner has issued a rejection on the basis of obviousness-type double patenting. Applicants have filed a terminal disclaimer with respect to this application.


It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: October 5, 2009

Respectfully submitted,

  
\_\_\_\_\_  
Seth H. Jacobs  
Attorney for Applicant(s)  
Reg. No. 32,140

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -3678